Cigna 1Q Revenue Rises on Evernorth Growth
By Kelly Cloonan
Cigna Group logged higher profit and revenue in its latest quarter as its pharmacy-benefit business Evernorth continues to grow, helping offset the company's divestiture of its Medicare and related businesses last year.
The healthcare company posted a first-quarter profit of $1.65 billion, or $6.26 a share, compared with $1.32 billion, or $4.85 a share, a year earlier.
Adjusted earnings per share were $7.79, compared with estimates of $7.60 a share according to analysts polled by FactSet.
Revenue rose about 5% to $68.49 billion, compared with analyst estimates of $66.29 billion.
Cigna said the growth was primarily driven by its Evernorth Health Services business, which includes pharmacy benefit services and specialty and care services. Adjusted revenue for Evernorth rose 9% in the quarter.
The growth was partially offset by a 21% decline in adjusted revenue for Cigna's namesake segment, which provides medical plans and other benefits. The decrease was driven by the company's divestiture of Medicare and related businesses last March, it said.
For the full year, the company now forecasts adjusted earnings per share of at least $30.35, up from its prior forecast of $30.25.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
April 30, 2026 06:15 ET (10:15 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
